Advertisement

Picture Kentro Design Corporate and Web Design Berlin 600x60px
Document › Details

AstraZeneca plc. (11/14/12). "Press Release: AstraZeneca Appoints Dr. Shridhar Narayanan to Lead Infection Research in Bangalore". Bangalore.

Region Region Bengaluru (Bangalore)
  Country India
Organisations Organisation AstraZeneca plc (LSE: AZN)
  Group AstraZeneca (Group)
  Organisation 2 Orchid Chemicals & Pharmaceuticals Ltd (IN)
Products Product anti-infective drug
  Product 2 drug discovery
     


AstraZeneca today announced it has appointed Dr. Shridhar Narayanan to the position of Vice President and Head, Infection iScience, Bangalore, effective November 2012. In this role, Dr. Narayanan will lead the AstraZeneca team of discovery research scientists who are based in Bangalore and focus on research for tuberculosis and neglected tropical diseases.

Dr. Narayanan joins AstraZeneca with more than 10 years of drug discovery and development experience. Most recently, Dr. Narayanan was the Executive Vice President-Discovery Biology and Drug Development at Orchid Chemicals and Pharmaceuticals. In this role, he was responsible for the design and implementation of the scientific and business strategy for drug discovery and development across therapeutic areas, managing a team of scientists in biology, DMPK, safety pharmacology and regulatory toxicology and clinical development.

Dr. Manos Perros, Head of the AstraZeneca Infection Innovative Medicines Unit said: "Dr. Narayanan and his team represent an important part of AstraZeneca's investment in the search for new medicines to help people who are suffering from infectious diseases. Dr. Narayanan's experience in the Indian pharmaceutical industry across various therapeutic areas will complement his strong team of scientists as they work closely with their infection research colleagues in Boston, Massachusetts as well as external academic leaders and other third party partners.

Dr. Narayanan holds a degree in Pharmaceutical Sciences, a Ph.D. in Pharmacology from Ohio State University, and has post-doctoral experience in Neuropharmacology at the University of California, Los Angeles. Following his training, Dr. Narayanan held scientific leadership positions at Nicholas Piramal, Glenmark, and Dr. Reddys.

- ENDS -

NOTES TO EDITORS

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com

   
Record changed: 2019-06-09

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px

More documents for AstraZeneca (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

SilverSky LifeSciences DxPx Conference 2019 Düsseldorf Medica 600x60px




» top